Organogenesis (NASDAQ:ORGO) Trading Down 3.7% on Insider Selling

Organogenesis (NASDAQ:ORGO)’s share price traded down 3.7% during mid-day trading on Friday following insider selling activity. The company traded as low as $5.50 and last traded at $5.5550. 209,215 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 1,449,700 shares. The stock had previously closed at $5.77.

Specifically, Director Glenn H. Nussdorf sold 200,000 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total value of $1,028,000.00. Following the completion of the transaction, the director directly owned 2,565,591 shares of the company’s stock, valued at $13,187,137.74. This represents a 7.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Wall Street Analysts Forecast Growth

ORGO has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organogenesis in a report on Monday. Finally, BTIG Research reissued a “buy” rating and set a $9.00 price objective on shares of Organogenesis in a research note on Monday, December 15th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.00.

Organogenesis Trading Down 2.9%

The company has a market cap of $710.70 million, a price-to-earnings ratio of -46.67 and a beta of 1.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32. The company’s 50 day moving average price is $4.88 and its 200 day moving average price is $4.51.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. The company had revenue of $150.86 million for the quarter, compared to analyst estimates of $134.10 million. Research analysts anticipate that Organogenesis will post -0.07 EPS for the current year.

Hedge Funds Weigh In On Organogenesis

Several large investors have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue bought a new position in Organogenesis in the third quarter worth $25,000. Quarry LP bought a new stake in shares of Organogenesis in the 3rd quarter valued at approximately $25,000. Farther Finance Advisors LLC acquired a new position in shares of Organogenesis in the 2nd quarter worth approximately $35,000. Ground Swell Capital LLC bought a new position in shares of Organogenesis during the second quarter valued at $39,000. Finally, Walleye Capital LLC acquired a new position in Organogenesis in the second quarter valued at about $45,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.